Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,845 total articles
HENSOLDT (HAGHY) has been marked down with the broader defense swoon, but the company's backlog exposure, JV pipeline in additive electronics, and attractive entry near $8.75 make a tactical long compelling. We lay out a mid-term (45 trading days) trade with clear entry, stop, and target, plus catalysts and risk controls.
Clearwater Analytics (CWAN) is currently trading below the $24.55 per-share buyout price agreed with Permira and Warburg Pincus. With deal terms public, activist support in the shareholder base and limited near-term execution risk, a long arbitrage-sized position at the current market price offers a modest absolute return and ~17% annualized upside…
Golar LNG (GLNG) combines long-duration charter backlog, operational FSRU/FLNG assets, and recent contract wins that make it a leveraged way to play higher LNG flows and rerouting after the Iran conflict. The company is capitalized at roughly $5.4B and carries near-term catalysts that can re-rate the stock, but leverage, negative EPS and project ex…
GDS has cleared a series of operational boxes — C-REIT progress, a $385M DayOne monetization and apparent post-earnings strength that the market is treating as an EBITDA beat plus improving pricing power. At a $9.41B market cap and with technicals showing bullish momentum, we lay out a mid-term trade: entry $43.20, stop $40.50, target $48.00 (about…
Thomson Reuters (TRI) has been punished this year even as its core Legal, Tax & Accounting, and Corporate content businesses continue to produce recurring revenue and pricing power. At a $40.3B market cap, 2.6% yield and a trailing P/E near 28, the stock looks mispriced relative to the durability of its cash flows and the optionality in AI-enabled …
Rubrik just delivered a quarter that beats on revenue and EPS, and its free cash flow is accelerating. The market has punished software names on AI disruption fears, but Rubrik's data-resilience positioning and a $238M quarterly free cash flow print argue for buying the pullback. This trade plan defines entry, stop and target for a mid-term window …
Nano Labs is trading at a tiny $72M market cap after a 2025 strategic pivot to crypto reserves and major expense cuts. The stock is cheap on simple book metrics and has a catalyst-rich runway (new hardware, BNB-focused programs, insider buying). This trade idea takes a tactical long position into the next earnings/operational update with defined en…
General Mills is trading at multi-year lows with a rich dividend, low P/E and an oversold technical backdrop. This trade idea argues for a phased accumulation with defined risk parameters: initial entry at $36.50, stop loss at $34.00 and a primary target of $46.00. The setup favors investors seeking income and value with a long-term horizon, while …
Axcelis Technologies (ACLS) is a capital-equipment beneficiary of the next memory capacity cycle and stands to gain scale if its pending Veeco merger closes. The company trades at a reasonable multiple, has strong cash generation and a light balance sheet. This trade idea lays out an actionable long with entry, stop and target tied to milestones an…
Micron is priced like a fast-grower but delivering the profitability and balance-sheet strength to justify it. At $428, the stock trades at ~20x forward earnings with 33% ROE, low leverage, and $10.3B of free cash flow. If AI demand and HBM tightness persist, the multiple can hold or expand; if capacity comes online and margins compress, downside i…
Goldman Sachs (GS) has pulled back roughly 20% from recent highs, dragging the stock into a valuation that looks attractive relative to earnings and book value. We lay out a mid-term trade: entry at $835.00, stop at $795.00, target $960.00, and a 45-trading-day horizon. The trade leans on a favorable P/E (~15), healthy ROE (13%), and demonstrable t…
Navigator Holdings (NVGS) owns the world's largest handysize liquefied gas fleet and has been adding ethylene-capable vessels. At a market cap of roughly $1.18B and a current price of $18.67, the stock trades at modest multiples while free cash flow remains pressured. We recommend a long-term buy for investors willing to hold through shipping cycli…
California Resources (CRC) is positioned to capture incremental realized price for its California-focused barrels as the Brent-WTI spread widens. With a $5.63B market cap, $543M in free cash flow, an improving capital structure and recent ESG certifications, CRC looks like a reasonable long trade for investors who want exposure to a domestic oil pr…
Lifeway Foods (LWAY) has traded like a special-situation takeover candidate since Danone surfaced with a $27 per-share bid. The board's rejection and subsequent governance noise pushed shares from a $34 high to the low-$17s, creating a simple thesis: underlying business strength (sales beats, healthy margins, strong returns) plus continued strategi…
UnitedHealth has been hit with broad-market volatility and sector rotation, but its earnings power, cash flow generation, and valuation argue for a tactical long. This trade idea lays out entry, target, stop, catalysts, and balanced risks for a mid-term rebound trade.
GoldMining Inc. (GLDG) delivered a positive initial PEA for its Whistler gold-copper project and continues to expand its resource pipeline across the Americas. At a $231.9M market cap and a deeply oversold technical setup, GLDG offers an asymmetric risk-reward for swing traders willing to take a medium-risk position while gold prices recover or pro…
Capital Southwest offers an attractive entry to capture a >10% yield while benefiting from refinancing tailwinds and a valuation that looks reasonable versus history. I’m upgrading CSWC to a Buy with a clear entry, stop and target for a mid-term swing trade.
Honeywell is an underappreciated industrial-software compounder trading below its recent highs after a pullback. The company combines high-margin software and automation businesses with a cash-generative aerospace franchise that management plans to spin off. At roughly $141B market cap and a free cash flow of $5.42B, the risk/reward looks favorable…
National HealthCare (NHC) is a cash-generative nursing and senior-living operator trading near $159 with a clean balance sheet, strong free cash flow and double-digit revenue growth last reported. This trade idea outlines a mid-term (45 trading days) long with precise entry, stop and target, backed by fundamentals and technicals while laying out ca…
Credo Technology (CRDO) builds the high-speed electrical interconnects that hyperscalers need to stitch GPUs together. After a monster revenue ramp and margin expansion, the market has pulled the stock down to $103.51, creating a tactical long opportunity. This trade idea lays out an entry at $103.51, a stop at $92.00, and a target of $155.00 with …
We upgrade Enghouse Systems (EGHSF) to a buy-rated trade idea. The chart is oversold, short interest is elevated and liquidity thin, creating asymmetric upside if IMG - a material business/partner issue - stabilizes. Trade plan: enter at $11.62, target $16.00, stop $9.50, mid-term horizon (45 trading days).
Graham Holdings (GHC) is trading at an attractive entry after a pullback. The company combines education, broadcasting, manufacturing and healthcare businesses, produces meaningful free cash flow ($275M last reported) and carries low leverage (debt/equity ~0.19). At a market cap ~ $4.5B and P/B ~0.94, the shares look mispriced relative to cash flow…
Domino's (DPZ) just confirmed why it remains one of the few restaurant names still growing through cycles: a dividend increase, steady same-store sales, strong free cash flow and a capital-light franchise model. The stock has pulled back toward the $365 low, presenting a tactical entry for traders willing to hold through a mid-term re-rating. This …
XPeng trades near $17.68 after a pullback that reflects delivery concerns. With market cap of about $16.9B, the stock offers upside to the $28 area if the company demonstrates that Q4 net profit and high gross margins are sustainable. This trade targets a recovery toward the 52-week high while protecting capital with a sensible stop below the recen…
Incyte is trading at a reasonable multiple against solid free cash flow, low leverage and attractive returns on capital. Clinical readouts and commercialization of late-stage dermatology assets create clear catalysts over the next 6 months. This trade targets a re-rating toward prior highs while limiting downside with a defined stop.
